Blue Trust Inc. Raises Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Blue Trust Inc. raised its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,273 shares of the biopharmaceutical company’s stock after buying an additional 8,772 shares during the period. Blue Trust Inc.’s holdings in Bristol-Myers Squibb were worth $1,773,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in BMY. Kingswood Wealth Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 3.5% during the fourth quarter. Kingswood Wealth Advisors LLC now owns 48,942 shares of the biopharmaceutical company’s stock worth $2,768,000 after purchasing an additional 1,634 shares during the period. Stonehage Fleming Financial Services Holdings Ltd bought a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $490,000. Drive Wealth Management LLC lifted its holdings in Bristol-Myers Squibb by 2.1% in the 4th quarter. Drive Wealth Management LLC now owns 8,878 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 182 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Bristol-Myers Squibb by 14.1% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 20,036 shares of the biopharmaceutical company’s stock worth $1,133,000 after buying an additional 2,469 shares during the last quarter. Finally, High Net Worth Advisory Group LLC increased its stake in shares of Bristol-Myers Squibb by 42.2% during the fourth quarter. High Net Worth Advisory Group LLC now owns 16,974 shares of the biopharmaceutical company’s stock valued at $960,000 after buying an additional 5,040 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Samit Hirawat purchased 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMY. UBS Group lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Truist Financial boosted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley raised their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Citigroup upped their target price on Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Finally, Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Trading Up 1.6 %

NYSE:BMY opened at $60.61 on Tuesday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10. The stock has a market cap of $122.93 billion, a price-to-earnings ratio of -16.88, a PEG ratio of 2.02 and a beta of 0.45. The company’s 50 day moving average price is $57.47 and its 200-day moving average price is $52.71. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same quarter last year, the company earned $2.00 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.09%. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.